141 related articles for article (PubMed ID: 17503315)
1. Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer.
Treiber G; Röcken C; Wex T; Malfertheiner P
Z Gastroenterol; 2007 May; 45(5):369-77. PubMed ID: 17503315
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Prete SD; Montella L; Caraglia M; Maiorino L; Cennamo G; Montesarchio V; Piai G; Febbraro A; Tarantino L; Capasso E; Palmieri G; Guarrasi R; Bianco M; Mamone R; Savastano C; Pisano A; Vincenzi B; Sabia A; D'Agostino A; Faiola V; Addeo R
Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
[TBL] [Abstract][Full Text] [Related]
5. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma.
Treiber G; Wex T; Röcken C; Fostitsch P; Malfertheiner P
J Cancer Res Clin Oncol; 2006 Nov; 132(11):699-708. PubMed ID: 16835748
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
7. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
13. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
15. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Jang JW; Bae SH; Choi JY; Oh HJ; Kim MS; Lee SY; Kim CW; Chang UI; Nam SW; Cha SB; Lee YJ; Chun HJ; Choi BG; Byun JY; Yoon SK
Cancer Chemother Pharmacol; 2007 Jan; 59(1):9-15. PubMed ID: 16614848
[TBL] [Abstract][Full Text] [Related]
16. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial.
Kirchhoff TD; Rudolph KL; Layer G; Chavan A; Greten TF; Rosenthal H; Kubicka S; Galanski M; Manns MP; Schild H; Gallkowski U
Eur J Surg Oncol; 2006 Mar; 32(2):201-7. PubMed ID: 16373084
[TBL] [Abstract][Full Text] [Related]
17. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
19. Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation.
Lee JO; Kim DY; Lim JH; Seo MD; Yi HG; Oh DY; Im SA; Kim TY; Bang YJ
J Gastroenterol Hepatol; 2009 May; 24(5):800-5. PubMed ID: 19175825
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
